Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-07 am EDT 		5-day change 1st Jan Change
4,232 JPY +0.69% Intraday chart for Takeda Pharmaceutical Company Limited +1.41% +4.39%
Jun. 06 Former Takeda Employee Pleads Guilty to Defrauding Company DJ
Jun. 06 Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
PU
Former Takeda Employee Pleads Guilty to Defrauding Company
DJ
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema
MT
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India
MT
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan
AQ
Transcript : Takeda Pharmaceutical Company Limited - Special Call
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
MT
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
MT
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861
CI
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
BU
GSK blood cancer drug nearly halves risk of death in late-stage trial
RE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
CI
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM
MT
Takeda Gets CHMP Approval for Recombinant ADAMTS13
DJ
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
CI
BHP pursuit of Anglo American highlights corporate-led UK M&A upswing
RE
Takeda Pharmaceutical : Other items which are provided electronically
PU
TAKEDA PHARMACEUTICAL : Form 6-K
PU
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited